Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
NC4-M52H9 | Mouse | Mouse NKG2A&CD94 Protein, His Tag |
![]() ![]() |
||
NC4-H52H3 | Human | Human NKG2A&CD94 Protein, His Tag |
![]() ![]() |
![]() ![]() |
|
NC4-R5258 | Rat | Rat NKG2A&CD94 Protein, Mouse IgG2a Fc Tag (MALS verified) |
![]() ![]() |
||
NC4-M5254 | Mouse | Mouse NKG2A&CD94 Protein, Fc Tag |
![]() ![]() |
||
NC4-M82F5 | Mouse | Biotinylated Mouse NKG2A&CD94 Protein, Fc,Avitag™ |
![]() ![]() |
||
NC4-C82F7 | Cynomolgus | Biotinylated Cynomolgus NKG2A&CD94 Protein, Fc,Avitag™ (MALS verified) |
![]() ![]() |
![]() ![]() |
|
NC4-H82E4 | Human | Biotinylated Human NKG2A&CD94 Protein, His,Avitag™ |
![]() ![]() |
![]() ![]() |
|
NC4-H5257 | Human | Human NKG2A&CD94 Protein, Fc Tag (MALS verified) |
![]() ![]() |
![]() ![]() |
|
NC4-C52H6 | Cynomolgus | Cynomolgus NKG2A&CD94 Protein, His Tag |
![]() ![]() |
![]() ![]() |
|
NC4-H82F5 | Human | Biotinylated Human NKG2A&CD94 Protein, Fc,Avitag™ |
![]() ![]() |
![]() ![]() |
|
NC4-H5253 | Human | Human NKG2A&CD94 Protein, Mouse IgG2a Fc Tag (MALS verified) |
![]() ![]() |
![]() ![]() |
Immobilized Anti-NKG2A Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Cynomolgus NKG2A&CD94, Fc,Avitag (Cat. No. NC4-C82F7) with a linear range of 0.1-16 ng/mL (QC tested).
The purity of Rat NKG2A&CD94 Protein, Mouse IgG2a Fc Tag (Cat. No. NC4-R5258) is more than 90% and the molecular weight of this protein is around 145-160 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Monalizumab | NNC-0141-0000-0100; NNC 0141-0000-0100; IPH-22XX; IPH-22; NN-8765; IPH-2201 | Phase 3 Clinical | Novo Nordisk A/S | Breast Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Mouth Neoplasms; Esophageal adenocarcinoma; Inflammation; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Genital Neoplasms, Female; Colorectal Neoplasms; Head and Neck Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Arthritis, Rheumatoid; Small Cell Lung Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Hematologic Neoplasms; Solid tumours | Details |
BMS-986315 | BMS-986315 | Phase 2 Clinical | Bristol-Myers Squibb Company | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
S-095029 | S-095029 | Phase 2 Clinical | Institut De Recherches Internationales Servier | Solid tumours; Mismatch Repair Deficient Cancer; Stomach Neoplasms; Esophageal Neoplasms; Microsatellite instability-high cancer; Carcinoma, Non-Small-Cell Lung | Details |
BRY-805 | BRY805; BRY-805 | Phase 1 Clinical | Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd | Solid tumours | Details |
HY000102 | HY-0102; HY-000102 | Phase 1 Clinical | Shanghai HyaMab Biotech Co Ltd | Solid tumours; Pancreatic Neoplasms | Details |
This web search service is supported by Google Inc.